Transcriptomics

Dataset Information

3

Heterogeneity of Response to Chemotherapy and Recurrence-free Survival in Neoadjuvant Breast Cancer: Results from the I-SPY 1 TRIAL


ABSTRACT: Introduction: The I-SPY 1 TRIAL was designed to evaluate complete pathologic response and tumor volume change, measured by magnetic resonance imaging (MRI), stratified by molecular subtypes and link response to 3-year recurrence free survival (RFS).Methods: Eligible patients had T =3 cm and received neoadjuvant chemotherapy with AC plus optional taxane. Serial MRI, biopsy, and blood draws were conducted over the course of treatment, and a database of multiple molecular profiles was assembled.Results: A total of 221 patients were eligible for analysis: median tumor size was 6.0 cm and median age was 49 years. The I-SPY 1 TRIAL patients had tumors with aggressive biology: 45% were estrogen receptor (ER) negative, 31% Her2+; and 91% high risk by the Netherlands Cancer Institute (NKI) 70-gene profile. After a median of 3.9 years, RFS was 77%. HR/HER2 status improved predictability of RFS with the greatest difference between HR+/HER2- and triple-negative disease (hazard ratio 0.39). Wound healing signature activation, p53 mutation, and Risk of Relapse (ROR) score were highly correlated and also significantly improved the accuracy of RFS predictions when added to stage. The rate of pathologic complete response (pCR) varied considerably from a low of 0-2% (NKI low risk, luminal A) to a high of 43-61% (17q Amplified, HER2 enriched, HR-/HER2+). Both pCR and the more refined residual cancer burden (RCB) were significant predictors of RFS for all patients and even more predictive when analyzed within biomarker subsets. Good risk (NKI low, ROR-S low risk, Wound Healing quiescent, p53 wild type) signatures were associated with significantly higher 3-year RFS than poor risk expression signatures (ROR-S high risk, Wound Healing Activated, p53 mutation, NKI high risk).Conclusion: Importantly, in this set of biologically poor prognosis tumors, pCR predicts for better outcome, especially when analyzed within breast cancer subsets. Keywords: reference x sample reference x sample

ORGANISM(S): Homo sapiens  

SUBMITTER: N Hylton   Charles Perou  Charles M Perou  L J Esserman 

PROVIDER: E-GEOD-22226 | ArrayExpress | 2012-01-13

SECONDARY ACCESSION(S): GSE22226PRJNA128867

REPOSITORIES: GEO, ArrayExpress

Similar Datasets

2012-01-13 | GSE22226 | GEO
2009-06-25 | E-GEOD-11877 | ArrayExpress
2010-06-24 | E-GEOD-10886 | ArrayExpress
2010-12-31 | E-GEOD-23312 | ArrayExpress
2010-10-25 | E-GEOD-15393 | ArrayExpress
| GSE11877 | GEO
2011-03-18 | E-GEOD-22358 | ArrayExpress
2012-12-01 | E-GEOD-34138 | ArrayExpress
2015-05-16 | E-GEOD-50952 | ArrayExpress
2013-09-03 | E-GEOD-41118 | ArrayExpress